Connection

MICHAEL A DAVIES to Gene Expression Regulation, Neoplastic

This is a "connection" page, showing publications MICHAEL A DAVIES has written about Gene Expression Regulation, Neoplastic.
  1. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
    View in: PubMed
    Score: 0.050
  2. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep. 2016 Jan 20; 6:19649.
    View in: PubMed
    Score: 0.043
  3. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.
    View in: PubMed
    Score: 0.043
  4. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 01; 74(23):7037-47.
    View in: PubMed
    Score: 0.039
  5. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol. 2014 Feb 01; 87(3):381-9.
    View in: PubMed
    Score: 0.037
  6. Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol. 2012 May; 39(5):493-9.
    View in: PubMed
    Score: 0.033
  7. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol. 2021 02; 141(2):303-321.
    View in: PubMed
    Score: 0.015
  8. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
    View in: PubMed
    Score: 0.014
  9. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
    View in: PubMed
    Score: 0.013
  10. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016 09; 240(1):84-95.
    View in: PubMed
    Score: 0.011
  11. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. 2015 Sep 01; 75(17):3554-67.
    View in: PubMed
    Score: 0.010
  12. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015 Jun; 3(6):602-9.
    View in: PubMed
    Score: 0.010
  13. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144.
    View in: PubMed
    Score: 0.009
  14. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
    View in: PubMed
    Score: 0.009
  15. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.